Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 12.155 -2.68% -0.34
BCRX closed up 2.88 percent on Wednesday, May 12, 2021, on 77 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BCRX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction -2.68%
BB Squeeze Started Range Contraction -2.68%
20 DMA Support Bullish 0.12%
50 DMA Support Bullish 0.12%
180 Bullish Setup Bullish Swing Setup 0.12%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.12%
Pocket Pivot Bullish Swing Setup -7.36%
Inside Day Range Contraction -7.36%
Wide Bands Range Expansion -7.36%
Crossed Above 20 DMA Bullish -5.92%
Older End-of-Day Signals for BCRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 5 minutes ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
Up 3% 1 day ago
10 DMA Support 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioCryst Pharmaceuticals, Inc. Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Diseases Chemical Compounds Influenza Coronavirus Enzymes Viruses Angioedema Drug Design Hereditary Angioedema Medicinal Chemistry Gout Kallikrein Seasonal Influenza Acetamides Crystallography Protease Inhibitor

Is BCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.24
52 Week Low 3.3
Average Volume 5,233,891
200-Day Moving Average 7.35
50-Day Moving Average 11.48
20-Day Moving Average 11.86
10-Day Moving Average 11.92
Average True Range 0.85
ADX 18.83
+DI 28.41
-DI 23.47
Chandelier Exit (Long, 3 ATRs ) 10.73
Chandelier Exit (Short, 3 ATRs ) 11.78
Upper Bollinger Band 13.14
Lower Bollinger Band 10.59
Percent B (%b) 0.75
BandWidth 21.42
MACD Line 0.33
MACD Signal Line 0.28
MACD Histogram 0.0566
Fundamentals Value
Market Cap 2.21 Billion
Num Shares 177 Million
EPS -1.15
Price-to-Earnings (P/E) Ratio -10.82
Price-to-Sales 14.96
Price-to-Book 26.95
PEG Ratio -0.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.65
Resistance 3 (R3) 13.58 13.12 13.45
Resistance 2 (R2) 13.12 12.83 13.16 13.39
Resistance 1 (R1) 12.81 12.65 12.97 12.88 13.32
Pivot Point 12.35 12.35 12.43 12.39 12.35
Support 1 (S1) 12.04 12.06 12.20 12.11 11.66
Support 2 (S2) 11.58 11.88 11.62 11.59
Support 3 (S3) 11.27 11.58 11.53
Support 4 (S4) 11.34